Form 4 for IDXX Idexx Laboratories
Accepted 2022-11-16 00:00:00 ET · period of report 2022-11-14 · accession 0001567619-22-020466 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-11-16 | 2022-11-14 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | S - Sale+OE | $434.47 | -10.5K | 70.8K | -13% | -$4.56M |
| D | 2022-11-16 | 2022-11-14 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | M - OptEx | $62.00 | +19.0K | 81.3K | +30% | +$1.18M |
| D | 2022-11-16 | 2022-11-14 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | M - OptEx | — | -19.0K | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-14 | S | D | 2,543 | $435.07 | 71,404.64 | D | — | — | (F3) Represents the weighted average price of the shares sold ranging from a low of $434.70 to a high of $435.67 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 2 | Common | Common Stock | 2022-11-14 | S | D | 6,385 | $434.26 | 73,947.64 | D | — | — | (F2) Represents the weighted average price of the shares sold ranging from a low of $433.69 to a high of $434.685 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 3 | Common | Common Stock | 2022-11-14 | S | D | 972 | $433.37 | 80,332.64 | D | — | — | (F1) Represents the weighted average price of the shares sold ranging from a low of $432.67 to a high of $433.65 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 4 | Common | Common Stock | 2022-11-14 | M | A | 18,998 | $62.00 | 81,304.64 | D | — | — | |
| 5 | Common | Common Stock | 2022-11-14 | S | D | 600 | $435.88 | 70,804.64 | D | — | — | (F4) Represents the weighted average price of the shares sold ranging from a low of $435.77 to a high of $436.04 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 6 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2022-11-14 | M | D | 18,998 | — | 0 | D | $62.00 · — to 2024-02-13 | 18,998 Common Stock | (F6) Not applicable. (F5) Grant of option to buy 9,499 shares of Issuer common stock that became exercisable for 8,244 shares in four equal annual installments beginning February 14, 2015 and for the remaining 1,255 shares on February 14, 2019 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. |